

Gentium S.p.A.  
Form 6-K  
June 06, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2006.

Commission File Number 000-51341

Gentium S.p.A.

(Translation of registrant's name into English)

Piazza XX Settembre 2, 22079 Villa Guardia (Como), Italy

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  
Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_.



Description of events affecting the Registrant are set forth in the Registrant's press release, dated June 6, 2006, attached hereto as Exhibit Number 1 and incorporated by reference herein in its entirety.

**Exhibit** **Description**

1 Press release, dated June 6, 2006.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**GENTIUM S.P.A.**

Date: June 6, 2006

By: /s/ Cary Grossman

Name: Cary Grossman

Title: Executive Vice President and Chief Operating Officer

---

**INDEX TO EXHIBITS**

**Exhibit Description**

1 Press release, dated June 6, 2006.

---

---

**PRESS RELEASE**

---

**FOR IMMEDIATE RELEASE**

Company Contact:

Cary Grossman  
Chief Operating Officer  
713-827-2104  
[cgrossman@gentium.it](mailto:cgrossman@gentium.it)

Investor Relations Contacts:

U.S.

Lippert/Heilshorn & Assoc.  
Kim Sutton Golodetz  
[Kgolodetz@lhai.com](mailto:Kgolodetz@lhai.com)  
Anne Marie Fields  
[afields@lhai.com](mailto:afields@lhai.com)  
212-838-3777

Italy:

Burson-Marsteller  
Luca Ricci Maccarini  
[luca\\_maccarini@it.bm.com](mailto:luca_maccarini@it.bm.com)  
+39 02.721431

**GENTIUM COMPLETES \$22.1 MILLION PRIVATE PLACEMENT**

**Villa Guardia (Como), Italy, June 6, 2006 - Gentium S.p.A. (NASDAQ NMS: GENT)** (the “Company”) announced today that it has completed its previously announced \$22.1 million private placement of 1,943,525 of its American Depository Shares (ADSs) at a price of \$11.39 per ADS. Investors in the financing also received warrants to purchase 388,705 ADSs at an exercise price of \$14.50 per ADS. Investors participating in the financing were large U.S. and Italian institutional investors. ThinkEquity Partners LLC acted as the lead placement agent for the offering, and Rodman & Renshaw LLC and I-Bankers Securities Incorporated were the co-agents.

The net proceeds from the offering will be used to fund the continued development of the Company’s product candidates and for general corporate purposes.

The ADSs sold in the private placement and the ADSs issuable upon exercise of the related warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission (SEC) or through an applicable exemption from SEC registration requirements. The ADSs were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the ADSs issued in the private placement and issuable upon exercise of the warrants.

### **About VOD**

Veno-Occlusive Disease (VOD) is a potentially life-threatening condition. Certain high dose chemotherapy and radiation therapies and stem cell transplantation (SCT) can damage cells of the blood vessels and result in VOD, a blockage of the small veins of the liver that can lead to liver failure and the failure of other organs (Severe VOD). SCT is a frequently used treatment following high dose chemotherapy and radiation therapy. The International Bone Marrow Transplant Registry estimated that approximately 45,000 people received blood and bone marrow transplants, which are types of SCT, in 2002. Based on the Company's review of more than 200 published papers, it believes that approximately 20% of patients who undergo SCT develop VOD, approximately one-third of those who develop VOD progress to Severe VOD, and approximately 80% of Severe VOD patients die within 100 days of the SCT. The Company believes that there are no approved therapies to treat or prevent VOD in the U.S. or the EU.

### **About Gentium**

Gentium S.p.A. is a biopharmaceutical company located in Villa Guardia (Como), Italy that is focused on the research, discovery and development of drugs derived from DNA extracted from natural sources, and drugs that are synthetic derivatives, to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate in the U.S., is an investigational drug that has been granted Orphan Drug status by the U.S. FDA to treat Severe VOD in recipients of stem cell transplants and Fast Track designation for the treatment of Severe VOD in recipients of stem cell transplants.

### **Cautionary Note Regarding Forward-Looking Statements**

*This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20F filed with the Securities and Exchange Commission under the caption "Risk Factors."*

###

---